<DOC>
	<DOCNO>NCT01216176</DOCNO>
	<brief_summary>The investigator propose conduct Phase I/randomized Phase II study design order test tolerability efficacy AZD0530 use together anastrozole therapy ER+ and/or PR+ , postmenopausal breast cancer . The Phase I pharmacokinetic ( PK ) cohort study ( cohort A ) postmenopausal woman metastatic breast cancer 2008-2009 show initial safety , tolerability good bioavailability drug determine dos use ongoing Phase II trial . In randomized Phase II cohort study ( cohort B ) , postmenopausal woman newly diagnose , previously untreated ER+ , HER2 negative breast cancer least 2 cm diameter clinical exam radiology randomize either neoadjuvant treatment anastrozole plus placebo , anastrozole combination AZD0530 . The Phase II cohort permit extend assay tolerability , initial estimate efficacy , investigation molecular predictor drug efficacy .</brief_summary>
	<brief_title>A Pharmacokinetic Randomized Trial Neoadjuvant Treatment With Anastrozole Plus AZD0530 Postmenopausal Patients With Hormone Receptor Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Saracatinib</mesh_term>
	<criteria>Inclusion Criteria Phase 1 ( Cohort A ) : Female patient ≥ 18 year Patient must postmenopausal , verify 1 following : Bilateral surgical oophorectomy No spontaneous menses &gt; 1 year No menses &lt; 1 year FSH estradiol level postmenopausal range Postmenopausal woman primary invasive breast cancer , histologically confirm core needle ( incisional biopsy ) , whose tumor estrogen ( ER ) and/or progesterone ( PgR ) positive . Estrogen and/or progesteronereceptor positive disease base 10 % nuclear stain invasive component tumor Stage IV disease ( define AJCC Staging Manual , 6th Edition , 2002 ) ; locally relapse , unresectable disease Measurable evaluable disease accord RECIST criterion ( see appendix VII ) Both HER2positive HER2negative disease ( define IHC fluorescence situ hybridization [ FISH ] ) . HER2+ must prior treatment trastuzumab and/or lapatinib . ECOG performance status 02 ( see appendix VI ) Patients suitable candidate treatment anastrozole ( patient may prior endocrine therapy prior chemotherapy treatment disease , either adjuvant therapy , treatment advanced disease ) . There restriction number prior regimens phase I cohort A . Patient accessible willing comply treatment followup Patient willing provide write informed consent prior performance studyrelated procedure Required laboratory value Absolute neutrophil count ≥ 1.5 x 10^9/L Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 100 x 10^9/L Creatinine ≤ 1.5 mg/dL Total bilirubin ≤ 1.0 x upper limit normal ( ULN ) Alkaline phosphatase AST/ALT within protocol parameter . In determine eligibility , abnormal two value ( AST ALT ) use . Inclusion Criteria Phase 2 ( Cohort B ) : Female patient ≥ 18 year Patient must postmenopausal , verify 1 following : Bilateral surgical oophorectomy No spontaneous menses ≥ 1 year No menses &lt; 1 year FSH estradiol level postmenopausal range Postmenopausal woman primary invasive breast cancer , histologically confirm core needle ( incisional biopsy ) , whose tumor estrogen ( ER ) and/or progesterone ( PgR ) positive . Estrogen and/or progesteronereceptor positive disease base 10 % nuclear stain invasive component tumor . Patients may bilateral multifocal invasive breast cancer . The patient may concurrent DCIS either breast DCIS measure part study endpoint . Tumor size ≥ 2 cm Tumor measurable either clinical examination , mammography , MRI , ultrasound HER2negative disease ( define fluorescence situ hybridization [ FISH ] IHC ) ECOG performance status 01 ( see Appendix VI ) Patient accessible willing comply treatment followup Patient willing provide write informed consent prior performance studyrelated procedure Required laboratory value Absolute neutrophil count ≥ 1.5 x 10^9/L Hemoglobin ≥ 9.0 g/dL Platelet count ≥ 70 x 10^9/L Creatinine ≤ 1.5 mg/dL Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) Alkaline phosphatase AST/ALT ≤ 1.5 x upper limit normal ( ULN ) Exclusion Criteria Phase 1 ( Cohort A ) : Concurrent therapy nonprotocol anticancer therapy Any agent estrogenic putatively estrogenic property , include herbal preparation , must stop least one week prior registration . Ongoing , chronic administration bisphosphonate therapy allow long treatment ongoing time study entry . Current therapy hormone replacement therapy , hormonal agent raloxifene , tamoxifen , selective estrogen receptor modulators ( agent must stop prior randomization ) Presence neuropathy ≥ grade 2 ( NCICTC version 3.0 ) baseline History malignancy within past 5 year , exception nonmelanoma skin cancer carcinomainsitu cervix Clinically significant cardiovascular disease ( e.g. , hypertension [ BP &gt; 150/100 ] , history myocardial infarction stroke within 6 month , unstable angina ) , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac arrhythmia require medication Active , uncontrolled infection require parenteral antimicrobial A history severe hypersensitivity reaction anastrozole , AZD0530 excipients Evidence bleed diathesis coagulopathy . Resting EKG measurable QTc interval &gt; 480msec 2 time point within 24 hr period . Since AZD0530 substrate inhibitor CYP3A4 , patient require medication drug list Appendix XI exclude study . Any evidence severe uncontrolled systemic medical psychiatric condition ( e.g . Severe hepatic impairment , interstitial lung disease [ bilateral , diffuse , parenchymal lung disease ] ) current unstable uncompensated respiratory cardiac condition make undesirable patient participate study could jeopardize compliance protocol Evidence underlie pulmonary dysfunction evidence oxygen saturation &lt; 90 % pulse oximetry , interstitial pulmonary infiltrates high resolution CT scan prior study entry and/or symptomatic pulmonary ( pleural parenchymal ) metastasis . Exclusion Criteria Phase 2 ( Cohort B ) : Prior chemotherapy , endocrine therapy radiotherapy present breast cancer . Prior incidence treatment contralateral invasive noninvasive breast cancer exclusion criterion . Inflammatory breast cancer , clinically define presence erythema induration involve onethird breast , pathologically define dermal lymphatic invasion Prior excisional biopsy complete resection primary invasive tumor ( prior sentinel node biopsy allow ) Prior ipsilateral radiation therapy invasive noninvasive breast cancer Distant metastasis exclusion criterion Isolated ipsilateral supraclavicular node involvement and/or direct invasion primary tumor skin allow Concurrent therapy nonprotocol anticancer therapy Any agent estrogenic putatively estrogenic property , include herbal preparation , must stop least one week prior registration Current therapy hormone replacement therapy , hormonal agent raloxifene , tamoxifen , selective estrogen receptor modulators ( agent must stop one week prior randomization ) Presence neuropathy ≥ grade 2 ( NCICTC AE version 3.0 ) baseline History malignancy within past 5 year , exception nonmelanoma skin cancer carcinomainsitu cervix Clinically significant cardiovascular disease ( e.g . history myocardial infarction stroke within 6 month , unstable angina ) , New York Heart Association ( NYHA ) Grade II great congestive heart failure , serious cardiac arrhythmia require medication Active , uncontrolled infection require parenteral antimicrobial A history severe hypersensitivity reaction anastrozole , AZD0530 excipients Evidence bleed diathesis coagulopathy Resting EKG measurable QTc interval &gt; 480msec 2 time point within 24 hr period . AZD0530 substrate inhibitor CYP3A4 . Since concurrent administration AZD0530 CYP3A4 substrates show well tolerate , continuation initiation medically indicate drug substrate CYP3A4 permit MD discretion . Drugs list Appendix XI know strongly induce inhibit CYP3A4 activity discontinue prior study entry initiate protocol treatment . Any evidence severe uncontrolled systemic psychiatric medical condition ( eg . Severe hepatic impairment , interstitial lung disease [ bilateral , diffuse , parenchymal lung disease ] ) current unstable uncompensated respiratory cardiac condition make undesirable patient participate study could jeopardize compliance protocol Evidence underlie pulmonary dysfunction evidence oxygen saturation &lt; 90 % pulse oximetry prior study entry and/or symptomatic pulmonary ( pleural parenchymal ) disease . Subjects unwilling unable undergo breast MRI require protocol exclude study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>Metastatic Phase I ONLY</keyword>
	<keyword>AZD0530</keyword>
	<keyword>Anastrozole</keyword>
	<keyword>Phase I metastatic disease</keyword>
	<keyword>Phase II newly diagnose breast cancer</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>PK</keyword>
	<keyword>Hormone Receptor</keyword>
	<keyword>Estrogen Receptor</keyword>
	<keyword>Progesterone Receptor</keyword>
	<keyword>ER+</keyword>
	<keyword>PR+</keyword>
	<keyword>HER negative</keyword>
	<keyword>Aromatase Inhibitors</keyword>
</DOC>